Mineralys Therapeutics, Inc. (MLYS)
(Delayed Data from NSDQ)
$13.46 USD
+0.05 (0.37%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $13.45 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Mineralys Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
MLYS 13.46 +0.05(0.37%)
Will MLYS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MLYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLYS
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why
Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?
MLYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy
Other News for MLYS
MLYS Crosses Below Key Moving Average Level
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference ...
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Insider Sell: Adam Levy Sells 73,678 Shares of Mineralys Therapeutics Inc (MLYS)
Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)